Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to asses...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Cervera-Carrascon, Victor, Quixabeira, Dafne C.A., Santos, Joao Manuel, Havunen, Riikka, Zafar, Sadia, Hemminki, Otto, Heiniö, Camilla, Munaro, Eleonora, Siurala, Mikko, Sorsa, Suvi, Mirtti, Tuomas, Järvinen, Petrus, Mildh, Markus, Nisen, Harry, Rannikko, Antti, Anttila, Marjukka, Kanerva, Anna, Hemminki, Akseli
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458667/
https://ncbi.nlm.nih.gov/pubmed/32923123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1761229
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge